Pharvaris BV receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pharvaris NV (PHVS)
Pharvaris NV stock price live, this page displays NASDAQ PHVS stock exchange data. View the PHVS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pharvaris NV real time stock price chart below.
What Is the Pharvaris NV Stock Price Today?
The Pharvaris NV stock price today is 24.00.
What Is the Stock Symbol for Pharvaris NV?
The stock symbol for Pharvaris NV is ""PHVS.""
What Stock Exchange Does Pharvaris NV Trade On?
Pharvaris NV is listed and trades on the NASDAQ stock exchange.
Is Pharvaris NV a Good Stock to Buy?
Determining whether Pharvaris NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHVS quote. (ISIN: NL00150005Y4)
What Is the Pharvaris NV Stock Price Today?
The Pharvaris NV stock price today is 24.00.
What Is the Stock Symbol for Pharvaris NV?
The stock symbol for Pharvaris NV is ""PHVS.""
What Stock Exchange Does Pharvaris NV Trade On?
Pharvaris NV is listed and trades on the NASDAQ stock exchange.
Is Pharvaris NV a Good Stock to Buy?
Determining whether Pharvaris NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHVS quote. (ISIN: NL00150005Y4)
NASDAQ
Currency in USD
Fair Value
An estimate of a Pharvaris NV's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.73
24.27
52 wk Range
11.51
26.33
PHVS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
1/2
Fair Value
An estimate of a Pharvaris NV's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.7324.27
52 wk Range
11.5126.33
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PHVS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Pharvaris NV's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
33.61
Upside
+40.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
8 analysts have revised their earnings upwards for the upcoming period
- Pharvaris BV receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 6K Pharvaris NV For: 12 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Pharvaris NV Company Profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Pharvaris NV SWOT Analysis
Promising HAE Drug | Pharvaris's deucrictibant shows superior efficacy in resolving HAE attacks, positioning it as a potential best-in-class oral treatment for both acute and prophylactic use. |
Financial Fortitude | With $397 million in cash, Pharvaris has a two-year runway to advance clinical trials, despite higher-than-expected R&D expenses and operating losses. |
Market Opportunity | Explore Pharvaris's potential to capture a significant share of the $2+ billion HAE market, with peak sales estimates of $500M for acute and $1.5B for prophylactic use. |
Analyst Outlook | JMP Securities maintains a "Market Outperform" rating with a $50 price target, reflecting confidence in deucrictibant's potential and Pharvaris's strong market positioning. |
Compare PHVS to Peers and Sector
Metrics to compare | PHVS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHVSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.8x | −0.9x | −0.6x | |
PEG Ratio | 0.28 | −0.01 | 0.00 | |
Price/Book | 8.1x | 0.7x | 2.6x | |
Price / LTM Sales | - | 3.2x | 3.3x | |
Upside (Analyst Target) | 36.7% | 279.3% | 39.0% | |
Fair Value Upside | Unlock | 6.7% | 4.9% | Unlock |
Analyst Ratings
9 Buy
0 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 33.61
(+40.06% Upside)
Earnings
Latest Release
Aug 12, 2025
EPS / Forecast
-0.83 / -0.7686
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Pharvaris NV Trade On?
Pharvaris NV is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Pharvaris NV?
The stock symbol for Pharvaris NV is "PHVS."
What Is the Pharvaris NV Market Cap?
As of today, Pharvaris NV market cap is 1.75B.
What Is Pharvaris NV's Earnings Per Share (TTM)?
The Pharvaris NV EPS (TTM) is -3.09.
When Is the Next Pharvaris NV Earnings Date?
Pharvaris NV will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is PHVS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Pharvaris NV Stock Split?
Pharvaris NV has split 0 times.
How Many Employees Does Pharvaris NV Have?
Pharvaris NV has 114 employees.
What is the current trading status of Pharvaris NV (PHVS)?
As of 26 Aug 2025, Pharvaris NV (PHVS) is trading at a price of 24.00, with a previous close of 23.65. The stock has fluctuated within a day range of 23.73 to 24.27, while its 52-week range spans from 11.51 to 26.33.
What Is Pharvaris NV (PHVS) Price Target According to Analysts?
The average 12-month price target for Pharvaris NV is USD33.61429402, with a high estimate of USD51.76409064 and a low estimate of USD15.87914003. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +40.06% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.